Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway

Biochemical Pharmacology

Volumn 52, Issue 2, 1996, Pages 237-245

  Hanif, Rashid ^a   Pittas, Anastasios ^a   Feng, Yan ^a   Koutsos, Markos I ^a   Qiao, Liang ^a   Staiano Coico, Lisa ^a   Shiff, Steven I ^a,b   Rigas, Basil ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

apoptosis; cell cycle; cell proliferation; colon cancer; NSAIDs; prostaglandins

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; SULINDAC SULFIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CELL CYCLE PHASE; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MORTALITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

EID: 0030602860     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00181-5     Document Type: Article

References (41)

1. 1. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF Jr, Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307-311, 1993.
2. 2. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A and Willett WC, Aspirin use and the risk for colorectal cancer in male health professionals. Ann Intern Med 121: 241-246, 1994.
3. 3. Waddell WR and Loughry RW, Sulindac for the polyposis of the colon. J Surg Oncol 24: 83-87, 1983.
4. 4-Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Brooker SV, Robinson CR and Offerhaus GJ, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 328: 1313-1316, 1993.
5. 5. Reddy B, Rao C, Rivenson A and Kelloff G, Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993.
6. 6. Pollard M and Luckert PH, Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214: 558-559, 1981.
7. 7. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR and Watson AJ, A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 156: 341-347, 1988.
8. 8. Pollard M, Luckert PH and Schmidt MA, The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 21: 57-61, 1983.
9. 9. Vane JR, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231: 232-235, 1971.
10. 10. Vargaftig B and Lefort J, Acute hypotension due to carrageenan, arachidonic acid and slow reacting substance C in the rabbit: Role of platelets and nature of pharmacological antagonism. Eur J Pharmacol 43: 125-141, 1977.
11. 11. Humes JL, Winter CA, Sadowski SJ and Kuehl FA Jr, Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal anti-inflammatory agents. Proc Natl Acad Sci USA 78: 2053-2056, 1981.
12. 12. Ferreira SH, Prostaglandins and non-steroidal anti-inflammatory drugs. In: Prostaglandins and Thromboxanes (Eds. Berti F, Samuelsson B and Velo GP), Vol. 13, pp. 353-361. Plenum Press, New York, 1977.
13. 13. Flower RJ, Moncada S and Vane JR, Analgesic-antipyretics and anti-inflammatory agents: Drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics (Eds. Gilman AG, Goodman LS and Gilman A), 6th Edn, pp. 682-698. Macmillan, New York, 1980.
14. 14. Biemond P, Swaak AG, Penders JA, Biendroff CM and Koster JF, Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis; In vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase. Ann Rheum Dis 45: 249-255, 1986.
15. 15. Momalski JS, Hirata F and Clark M, Aspirin inhibits phospholipase C. Biochem Biophys Res Commun 139: 115-121, 1986.
16. 16. Siegel MI, Mcconnell RT and Cuatrecasas P, Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc Natl Acad Sci USA 76: 3774-3778, 1979.
17. 17. Shiff SJ, Qiao L, Tsai L-L and Rigas B, Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
18. 18. Shiff SJ, Koutsos MI, Qiao L and Rigas B, Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp Cell Res 222: 179-188, 1996.
19. 19. Rigas A and Levine L, Arachidonic acid metabolism by rat liver cells (the C-9 cell line). J Pharmacol Exp Ther 231: 230-235, 1984.
20. 20. Levine L, Measurement of arachidonic acid metabolites by radioimmunoassay. In: Manual of Clinical and Laboratory Immunology (Eds. Fahey JL, Friedman H and Rose NR), 3rd Edn. American Society for Microbiology, Washington, DC, 1986.
21. 21. Elstein KH and Zucker RM, Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations. Exp Cell Res 211: 322-331, 1994.
22. 22. Darzynkiewicz Z, Bruno S, del Bino S, Gorczyca W, Hotz MA, Lassota P and Traganos F, Features of apoptotic cells by flow cytometry. Cytometry 13: 795-808, 1992.
23. 23. Darzynkiewicz Z, Differential staining of DNA and RNA in intact cells and isolated cell nuclei with acridine orange. Methods Cell Biol 33: 285-298, 1990.
24. 24. Wyllie AH, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activity. Nature 284: 555-556, 1980.
25. 25. Cohen JJ, Apoptosis. Immunol Today 14: 126-130, 1993.
26. 26. Hla T and Neilson K, Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992.
27. 27. Funk CD and FitzGerald GA, Eicosanoid forming enzyme mRNA in human tissues. Analysis by quantitative polymerase chain reaction. J Biol Chem 266: 12508-12513, 1991.
28. 28. Funk CD, Funk LB, Kennedy ME, Pong AS and FitzGerald GA, Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 5: 2304-2312, 1991.
29. 29. Cole OF, Fan TP and Lewis GP, Release of eicosanoids from cultured rat aortic endothelial cells: Studies with arachidonic acid and calcium ionophore A23187. Cell Biol Int Rep 10: 407-413, 1986.
30. 30. Hassid A and Levine L, Stimulation of phospholipase activity and prostaglandin biosynthesis by mellitin in cell culture and in vivo. Res Commun Chem Pathol Pharmacol 18: 507-517, 1977.
31. 31. Hong SL, Polsky-Cynkin R and Levine L, Stimulation of prostaglandin biosynthesis by vasoactive substances in methylcholanthrene-transformed mouse BALB/3T3. J Biol Chem 251: 776-780, 1976.
32. 32. Hubbard WC, Alley MC, McLemore TL and Boyd MR, Fatty acid cyclooxygenase metabolism of arachidonic acid in human tumor cells. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury (Eds. Honn KV, Marnett LJ, Nigam S and Walden T Jr), pp. 27-32. Kluwer Academic Publishers, Norwell, MA, 1989.
33. 33. Grilli M, Chiu J-S and Lenardo MJ, NF-kB and Rel: Participants in a multiform transcriptional regulatory system. Int Rev Cytol 143: 1-62, 1993.
34. 34. Kopp E and Gosh S, Inhibition of NF-kB by sodium salicylate and aspirin. Science 265: 956-958, 1994.
35. 35. Beaven MA, de Mello MCF, Hial V and Horakova Z, In vitro inhibition of cell proliferation by anti-inflammatory drugs. Fedn Proc 36: 1037, 1977.
36. 2) against indomethacin. J Cancer Res Clin Oncol 108: 239-242, 1984.
37. 37. Swanson BN, Boppana VK, Vlasses PH, Holmes GI, Monsell K and Ferguson PK, Sulindac disposition when given once and twice daily. Clin Pharmacol Ther 32: 397-403, 1982.
38. 38. Duggan DE, Hare LE, Ditzler CA, Lei BW and Kwam KC, The disposition of sulindac. Clin Pharmacol Ther 21: 326-335, 1977.
39. 39. Strong HA, Warner MJ, Renwick AG and George CF, Sulindac metabolism: The importance of an intact colon. Clin Pharmacol Ther 38: 387-393, 1985.
40. 40. Waddell WR, Ganser GF, Cerise EJ and Loughry RW, Sulindac for polyposis of the colon. Am J Surg 157: 175-179, 1989.
41. 41. Duggan DE, Hooke KF and Hwang SS, Kinetics of the tissue distributions of sulindac and metabolites: Relevance to sites and rates of bioactivation. Drug Metab Dispos 8: 241-246, 1980.